338 related articles for article (PubMed ID: 26347494)
1. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
2. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
3. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer.
Goodman KA; Julie D; Cercek A; Cambridge L; Woo KM; Zhang Z; Wu AJ; Reidy DL; Segal NH; Stadler ZK; Saltz LB
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1087-1095. PubMed ID: 28721892
[TBL] [Abstract][Full Text] [Related]
5. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C
Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
7. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
8. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
9. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
10. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
12. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Flam M; John M; Pajak TF; Petrelli N; Myerson R; Doggett S; Quivey J; Rotman M; Kerman H; Coia L; Murray K
J Clin Oncol; 1996 Sep; 14(9):2527-39. PubMed ID: 8823332
[TBL] [Abstract][Full Text] [Related]
13. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
[TBL] [Abstract][Full Text] [Related]
15. Feasibility and Outcome of Routine Use of Concurrent Chemoradiation in HIV-positive Patients With Squamous Cell Anal Cancer.
Leiker AJ; Wang CJ; Sanford NN; Aguilera TA; Karri S; Beg MS; Kazmi SA; Olson C; Matthews JA; Abdelnaby A; Meyer JJ; Folkert MR
Am J Clin Oncol; 2020 Oct; 43(10):701-708. PubMed ID: 32694298
[TBL] [Abstract][Full Text] [Related]
16. Review of anal cancer patients at the Ottawa hospital.
Abunassar M; Reinders J; Jonker DJ; Asmis T
Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
[TBL] [Abstract][Full Text] [Related]
17. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal.
White EC; Khodayari B; Erickson KT; Lien WW; Hwang-Graziano J; Rao AR
Am J Clin Oncol; 2017 Aug; 40(4):386-392. PubMed ID: 25513996
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
